Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 6 457-459, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Increased expression of the cyclin D1 gene in Barrett's esophagus

N Arber, C Lightdale, H Rotterdam, KH Han, A Sgambato, E Yap, H Ahsan, J Finegold, PD Stevens, PH Green, H Hibshoosh, AI Neugut, PR Holt and IB Weinstein
Columbia-Presbyterian Cancer Center, Columbia University, New York, New York 10032, USA.

Previous studies have found a 3-10-fold amplification and overexpression of the cyclin D1 gene in about 32% of human esophageal squamous cell carcinoma. The purpose of this study was to evaluate the prevalence of increased expression of the cyclin D1 protein in Barrett's esophagus. Using 69 formalin-fixed and paraffin-embedded human esophageal specimens, which had been removed endoscopically or obtained at surgery during 1993 and 1994, all immunohistochemical analyses were performed using an avidin-biotin complex immunoperoxidase technique. Increased nuclear expression of the cyclin D1 protein was noted in 32 of 69 samples (46%; 44% of the samples from males and 50% of the samples from females). Positive nuclear staining for the cyclin D1 protein in Barrett's disease with intestinal metaplasia was found in 38% of the male cases and 25% of the female cases, whereas in gastric metaplasia it was positive in 33% of men and 48% of women. Nuclear accumulation of the cyclin D1 protein was also found in both dysplastic and nondysplastic lesions, and it was not associated with sex, age, or cigarette or alcohol consumption. Samples from patients taking proton pump inhibitors tended to be less frequently positive (32%) for cyclin D1 nuclear staining when compared to patients taking H2 antagonists (45%) or antacids (55%). These studies suggest that increased expression of cyclin D1 is an early event in the tumorigenic process of esophageal adenocarcinomas and that the increased expression of this gene might predispose the epithelium to malignant transformation.

This article has been cited by other articles:

				M. di Pietro, C. J. Peters, and R. C. Fitzgerald Clinical puzzle: Barrett's oesophagus Dis. Model. Mech., July 1, 2008; 1(1): 26 - 31. [Abstract] [Full Text] [PDF]

				E. Zagorowicz and J. Jankowski Molecular changes in the progression of Barrett's oesophagus Postgrad. Med. J., August 1, 2007; 83(982): 529 - 535. [Abstract] [Full Text] [PDF]

				J. G. Izzo, T.-T. Wu, X. Wu, J. Ensor, R. Luthra, J. Pan, A. Correa, S. G. Swisher, C. K.S. Chao, W. N. Hittelman, et al. Cyclin D1 Guanine/Adenine 870 Polymorphism With Altered Protein Expression Is Associated With Genomic Instability and Aggressive Clinical Biology of Esophageal Adenocarcinoma J. Clin. Oncol., February 20, 2007; 25(6): 698 - 707. [Abstract] [Full Text] [PDF]

				M. R. Anderson, R. Harrison, P. A. Atherfold, M. J. Campbell, S. J. Darnton, J. Obszynska, and J. A.Z Jankowski Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin. Cancer Res., October 15, 2006; 12(20): 5936 - 5943. [Abstract] [Full Text] [PDF]

				S L Preston and J A Jankowski Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full! Gut, October 1, 2006; 55(10): 1377 - 1379. [Full Text] [PDF]

				J. C. Finley, B. J. Reid, R. D. Odze, C. A. Sanchez, P. Galipeau, X. Li, S. G. Self, K. A. Gollahon, P. L. Blount, and P. S. Rabinovitch Chromosomal Instability in Barrett's Esophagus Is Related to Telomere Shortening. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1451 - 1457. [Abstract] [Full Text] [PDF]

				H. K. Roy, D. P. Kunte, J. L. Koetsier, J. Hart, Y. L. Kim, Y. Liu, M. Bissonnette, M. Goldberg, V. Backman, and R. K. Wali Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/{beta}-catenin signaling. Mol. Cancer Ther., August 1, 2006; 5(8): 2060 - 2069. [Abstract] [Full Text] [PDF]

				R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]

				D. T. McManus, A. Olaru, and S. J. Meltzer Biomarkers of Esophageal Adenocarcinoma and Barrett's Esophagus Cancer Res., March 1, 2004; 64(5): 1561 - 1569. [Abstract] [Full Text] [PDF]

				M. D. Gammon, M. B. Terry, N. Arber, W.-H. Chow, H. A. Risch, T. L. Vaughan, J. B. Schoenberg, S. T. Mayne, J. L. Stanford, R. Dubrow, et al. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 34 - 39. [Abstract] [Full Text] [PDF]

				P. C. Enzinger and R. J. Mayer Esophageal Cancer N. Engl. J. Med., December 4, 2003; 349(23): 2241 - 2252. [Full Text] [PDF]

				N J Trudgill, S K Suvarna, J A Royds, and S A Riley Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction Mol. Pathol., December 1, 2003; 56(6): 313 - 317. [Abstract] [Full Text] [PDF]

				L. Y. Y. Fong, R. Mancini, H. Nakagawa, A. K. Rustgi, and K. Huebner Combined Cyclin D1 Overexpression and Zinc Deficiency Disrupts Cell Cycle and Accelerates Mouse Forestomach Carcinogenesis Cancer Res., July 15, 2003; 63(14): 4244 - 4252. [Abstract] [Full Text] [PDF]

				K. Bani-Hani, I. G. Martin, L. J. Hardie, N. Mapstone, J. A. Briggs, D. Forman, and C. P. Wild Prospective Study of Cyclin D1 Overexpression in Barrett's Esophagus: Association With Increased Risk of Adenocarcinoma J Natl Cancer Inst, August 16, 2000; 92(16): 1316 - 1321. [Abstract] [Full Text] [PDF]

				N A SHEPHERD Barrett's oesophagus and proton pump inhibitors: a pathological perspective Gut, February 1, 2000; 46(2): 147 - 149. [Full Text] [PDF]